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Burden and prevention of HPV related diseases:
Situation in Croatia
Abstract
The role of persistent infection of high-risk human papillomaviruses
(HR-HPV) in cervical cancer has become convincingly established. Other
anogenital cancers in women and men are also caused, to a lesser extent, by
HR-HPV. In addition, most of the benign anogenital warts and laryngeal
papillomatosis are caused by low-risk (LR) HPV types. All these HPV-asso-
ciated diseases represent high public health burden worldwide, cervical
cancer being the leading one. Nowadays, several opportunities are available
to prevent cervical cancer and other HPV-related diseases. The most promis-
ing cancer preventing intervention is the HPV vaccination against the most
common HPV types (16 and 18). However, secondary prevention like edu-
cation and early detection of the disease by screening has demonstrated in
the past great efficacy and should be continued and improved by novel prog-
nostic methods (HPV testing and other biomarkers) in countries where it is
already in place, and implemented in those countries that lack cancer
control programmes. Herein, the current knowledge on HPVs, HPV-related
diseases and their preventive approaches are discussed. In addition, the
situation in Croatia is presented.
INTRODUCTION
In the early 1970s, studies were initiated on the possible role of humanpapillomaviruses (HPV) in cancers (1). Today it is well established
that this very heterogeneous virus family comprehend important hu-
man carcinogenic viruses, causing not only the vast majority of cervical,
but also a substantial proportion of other anogenital and head and neck
cancers. In addition, specific types have been linked to certain cuta-
neous cancers. HPV infections on a global scale account for more than
50% of infection-linked cancers in females and for approximately 5% in
males (2). Vaccines against the high-risk (HR) HPV types 16 and 18 re-
present the first preventive vaccines directly developed to protect against
one of the leading human cancers (cervical carcinoma). This review
will cover the essentials about HPVs, the epidemiology and prevention
of the major cancer and diseases caused by them, and it will discuss the
situation in Croatia.
HUMAN PAPILLOMAVIRUSES
HPV is a strictly epitheliotropic, circular double-stranded DNA virus
infecting human mucosal and cutaneous tissues. More than 100 HPV
genotypes have been characterized. Approximately 40 types infect the
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Overview
anogenital tract mucosa, while others infect cutaneous
tissues (3). Since the discovery of the HPV genome the
presence of viral infection has been evaluated by the
detection of viral DNA as viral isolation on cell culture is
extremely difficult and natural serology response to viral
infection is very weak and often uninformative.
Based on ample scientific evidence, in 1995 a working
group of the IARC concluded that some HPV types, also
called HR types, are carcinogenic to humans (4). These
carcinogenic HPV types can also cause other anogenital
cancers in women (vulvar, vaginal and anal cancers) and
men (penile and anal cancers), as well as oropharyngeal
tumors. Genital HPV types also have a role in squamous
cell carcinoma (SCC) of the conjunctiva, but no conclu-
sion could be reached for cancer of the esophagus, lung,
colon, ovary, breast, prostate, urinary bladder, or nasal
and sinonasal cavities (4).
In contrast to the HR types, low-risk (LR) HPV types,
notably types 6 and 11, cause almost all clinically visible
benign lesions, i.e. genital warts (flat and acuminate
condylomata) and laryngeal papillomas. In the last clas-
sification, there are three main categories of HPV relative
to cervical cancer: carcinogenic (high-risk types 16, 18, 31,
33, 35, 39, 45, 51, 52, 56, 58, 59), probably carcinogenic
(type 68) and possibly carcinogenic (types 26, 30, 34, 53,
66, 67, 69, 70, 73, 82, 85, 97) (Bouvard 2009). In a recent
worldwide survey, HPV 16 was the most prevalent type in
cervical cancer (61%), followed by HPV 18 (10%), HPV
31 (4%), HPV33 (4%), HPV35 (2%), HPV45 (6%),
HPV52 (3%) and HPV58 (2%) (5) (Table 1).
HPV infection is very common at young age (under
25 years). HPV infections are generally transient, with
60-70% of new infections clearing within one year and
91% clearing within two years (6). Only a small propor-
tion of HPV infections progress to persistent infection,
often involving HR HPV types that have been shown to
persist longer than LR-HPV types. The estimated aver-
age global prevalence of genital HPV infection is 12%
(7). The prevalence among women with normal cytology
varies between countries from 2 to 42% and depends on
the age and population risk (8). High prevalence was
observed in Africa and Latin America compared to Euro-
pe, North America and Asia.
Besides genital warts, most HR-HPV infections resol-
ve without appearance of any symptoms or in some cases
with the occurrence of atypical or low-grade cervical
lesion (CIN 1, cervical intraepithelial neoplasia grade 1).
Only a small proportion (10-30%) of HR-HPV infection
that persists for a long time (several years) poses a risk for
the development of high-grade cervical lesions (CIN 2
and 3) that are precursor lesions of invasive cervical
cancer (ICC). For instance, CIN 2 lesion will progress to
CIN 3 lesion within 2 to 4 years (9). However, for the
majority of HPV positive women the precancerous le-
sion disappears at the same time the HPV infection has
cleared. Thus, a small proportion (about 1%) of low
grade lesion (CIN 1) and 12% of high grade lesions
(CIN3) will progress into invasive cancer if left untreated
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(10). Progression of precursor lesions to ICC usually
takes place over a period of more than 10 years, allowing
time for the identification and treatment of precursors
before cancer develops (Figure 1).
The most prevalent HR-HPV types in Croatian wo-
men with precancerous lesions (high-grade squamous
cell intraepithelial lesion [HSIL]) were, as expected, HPV
16 (23%) followed by HPV 31 (12%), HPV 33 (6.1%),
HPV 18 (5%), HPV 52 (2.3%), HPV 58 (1.1%) and HPV
45 (0.9%) (11) (Figure 2). It is important to note that
LR-HPV 6/11 was present in 7% of HSIL cases (data not
shown). The HSIL lesions positive for LR-HPV types
will probably clear and the lesion will regress, while those
lesions that are associated with HR-HPV types have a
higher risk of progression to invasive cervical cancer.
Cervical cancer precursor lesions persist longer and
progress more quickly in women with HPV 16 and/or 18
infections than in women with other HR-HPV types and
LR-HPV types (12). HPV 16 and 18 positive women
have a 200-fold increased risk of cervical cancer (13).
Factors that may influence progression (Figure 1) include
co-infection with other sexually transmitted infections
such as Chlamydia trachomatis, herpes simplex virus (HSV)
or human immunodeficiency virus (HIV), tobacco smok-
ing, high parity (>3 children) and immune suppression
(organ graft recipients or acquired immunodeficiency
syndrome [AIDS] patients) (14). The role of nutrition
and long-term use of oral contraceptives in cervical can-
cerogenesis is still unclear.
Period biol, Vol 114, No 2, 2012. 177
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Figure 1. Risk factors, natural history of human papillomavirus (HPV) infection, cervical cancerogenesis and opportunities for cervical cancer
control; pre-invasive cervical lesions or cervical intraepithelial neoplasia (CIN) grade 1 to 3 that may progress to invasive cervical cancer (ICC).
Figure 2. Prevalence of specific human papillomavirus (HPV) types
including single and multiple infections in high-grade squamous cell
intraepithelial cervical lesion (HSIL) in Croatia (11).
In addition to carcinogenic alpha-HPV types (muco-
sotropic), several beta-HPV types, notably HPV types 5
and 8, are associated with SCC of the skin and thus
considered possibly carcinogenic to humans (4). Data for
this association is strong in patients with Epidermodys-
plasia verruciformis (EV), but less so in general popula-
tion. EV is a rare genetically heterogeneous disease, either
autosomal recessive or X-linked but also associated with
a high-risk of non-melanoma skin cancer (15). EV is a
unique model where genetic susceptibility to HPVs is
demonstrated. In 75% of EV-patients, one of two related
genes, EVER1 or EVER2, has a non-sense mutation.
The complex of zinc-transporting proteins EVER1,
EVER2, and ZnT-1 that maintain cellular zinc homeo-
stasis plays a central role in the HPV-specific barrier
which protects cells against infection with beta-HPVs
(16).
HPV induced cancerogenesis
The HPV genome contains several early and late
open reading frames coding for replication and tran-
scription regulating proteins, E1, E2, E5, E6, E7 and
viral capsid proteins, L1 and L2, respectively. Two early
proteins, E6 and E7, act as major viral oncoproteins
178 Period biol, Vol 114, No 2, 2012.
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Figure 3. Schematic presentation of essential cell cycle signaling pathways (A) and the interference of the HPV E6 and E7 oncoproteins (B).
which, besides being over-expressed in HPV-associated
cancers, have potent transforming activity in tissue cul-
ture and tumorigenic action in transgenic mice (12).
The key activity of E7 protein is to overcome tumor
suppressor block controlled by the retinoblastoma pocket
protein (pRB), while that of E6 protein is to overcome
the p53 protective control pathways which are important
in preventing the genetic damage leading to cellular
transformation. Thus, these oncoproteins promote gene-
tic instability through induction of cellular proliferation,
disruption of cell cycle checkpoints, inhibition of apop-
tosis, induction of telomerase activity, and finally lead to
cancer (Figure 3).
Briefly, in quiescent cells, pRB is present in a hypo-
phosphorylated form and associates with E2F transcrip-
tion factor, thereby inhibiting their transcriptional acti-
vity (Figure 3A). Under exposure to a mitogenic signal,
complexes of cyclin and cyclin-dependent kinase (CDK)
are activated, notably cyclin D1-CDK4 and cyclin D1-
-CDK6 complexes, which induce pRB phosphorylation
leading to the disruption of pRB/E2F complexes. Such
activated E2F transcription factors then induce cyclin E
and subsequent additional phosphorylation of RB by
cyclin E-CDK2 complex that initiates entry into S phase.
The protein p16INK4A (p16) mediates senescence and
differentiation by inhibiting cyclin D1-CDK4 and cyclin
D1-CDK6 complexes. The interplay between the cyc-
lins, CDKs and their inhibitors determines whether the
restriction point (R on Figure 3) can be passed. A second
important control mechanism of the cell cycle occurs
during the G2 phase, when p53 plays a crucial role
during DNA replication. Usually, p53 is maintained at
low concentrations by MDM2-mediated degradation but
when replication errors or other DNA damages occurs
the checkpoint kinases CHK1 and CHK2 induce in-
creased p53 activity by phosphorylation of various down-
stream molecules, including p53 itself. The p53 tetramer
acts as a stress-induced transcription factor and induces
the expression of p21CIP (p21) which inhibits several
cyclin-CDK complexes and stops the cell cycle allowing
correction of DNA errors or induction of apoptosis if the
damage is too extensive. Besides its crucial role in cell
cycle control, p53 is also a master regulator of many other
stress-associated cellular functions, and is therefore often
inactivated or mutated in many different cancer types
(17).
Upon HPV infection, the E7, when binding to pRB
and its related members (p107 and p130), mimics the
effects of pRB phosphorylation resulting in the release of
active E2F transcription factors which in turn activate
the transcription of a group of genes encoding proteins
essential for cell cycle progression (Figure 3B). Thus, E7
expressing cells can enter the S phase in the absence of
mitogenic signals (17). E7 also binds and activates com-
plexes of cyclins and CDKs which control progression
through the cell cycle. On the other hand, E6 associates
with the ubiquitin-protein ligase E6AP which then binds
to p53 and targets the p53 protein for multi-ubiquitina-
tion and consequent proteasomal degradation (18) (Fig-
ure 3B). HPV oncoproteins E7 and E6, both have multi-
ple other functions by binding numerous target proteins
and degrading some via proteasomal degradation, i.e.
family proteins of pRB (p107, p130) (19), and p53 (p63,
p73) (18), and p21(CIP1) protein (20).
In conclusion, expression of E6 and E7 viral oncopro-
teins allows infected cells to re-enter or remain in the cell
cycle and furthermore inhibits p53-mediated apoptosis,
which consequently allows the virus to replicate as it is
otherwise dependent on the host cell DNA replication
machinery. Both HR and LR-HPV oncoproteins bind
their target proteins but HR do this with higher affinity
and also degrade them unlike LR-HPV oncoproteins
(21).
Immunology of HPV infection
Natural HPV infection of the genital tract gives rise to
a slow and modest serum antibody response in most but
not all infected individuals. Humoral response to HPV
infection is limited to only 50-80% of women with per-
sistent infection seroconvert, while incident infections
very rarely lead to seroconversion, which usually occurs
from 6-18 months from infection (22).
Presentation of viral antigens, major capsid protein
(L1) and the minor capsid protein (L2) (23) to the host
immune system is limited as the HPV infection is re-
stricted to epithelial cells. Virus-neutralizing anti-L1 anti-
bodies are essentially type-specific. As the L2 protein is
situated more internally into the capsid, the anti-L2 anti-
bodies are less potent than anti-L1 antibodies, but they
appear to show some cross-reactivity to heterologous
HPV types (24). Antibody responses against E6 and E7
proteins from HPV 16 are most prevalent in patients
with advanced cervical cancer and as such do not have
prognostic value (25).
Innate immunity, also known as non-specific immu-
ne response is as important as the adaptive immunity in
case of HPV infection. The first line of defense is the skin
or mucosa, which are either a layer of keratinized cells
that provide a physical barrier against HPV entry or
mucin that the cells release on the mucosal surface. This
is the reason why HPV are thought to infect cells only
after micro-lesions of the skin or mucosa (26). Innate
immunity additionally activates interferon response,
macrophages and natural killer (NK) cells to help clear
the infection. Finally, innate immunity has a significant
role in activating and directing later activated adaptive
immunity for the HPV clearance. However, as HPV life
cycle is exclusively linked with differentiating keratino-
cytes (27) there is limited opportunity for immune sys-
tem activation as in the lower layers of the epithelium
only few viral proteins are expressed at low levels. Furt-
hermore, the virus does not kill or destroy infected cells
but is shed when those cells undergo programmed apop-
tosis as a part of their terminal differentiation programme.
Thus, during HPV active infection there is no inflam-
mation that would otherwise activate the immune re-
sponse. And finally, viral particles are released out of the
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epithelium where they cannot efficiently activate host
immunity (22). In addition to the specific life cycle that
efficiently hides the virus from the immune system, HPV
proteins directly interfere with several aspects of immune
system (28).
Despite all the mechanisms of immune evasion that
HPV employs, adaptive immunity does play a role in the
clearance of infection. Thus, in specific cell-mediated
immune response dendritic cells (or Langerhans cells),
present in the cervical epithelium, play an important role
in recognizing HPV-infected cells and stimulate T hel-
per 1 (Th1) cells, which elicits the production of cyto-
toxic T-lymphocytes (29). It was shown that regressing
genital warts contain infiltrating cytotoxic T-lymphocy-
tes and macrophages (30). Furthermore, it was shown
that in immunocompromised patients (i.e. HIV positive
patients) HPV-induced lesions recur more often after
treatment (31).
HR HPV-RELATED DISEASES
Cervical cancer
Cervical cancer is the third most common cancer,
after breast and colorectal cancer, among women world-
wide, with 529,500 estimated new cases and 275,000
deaths in the year 2008 (32) (Table 1). It accounts for
8.8% of all female cancer cases with the estimated in-
cidence and mortality rates (world age standardised rate
[WASR]) of 15.2 and 7.8 per 100,000, respectively. Cervi-
cal cancer is the second most common cancer in develop-
ing regions (452,000 cases representing 85% of all cervi-
cal cancer cases or 15% of female cancers) and only the
10th most common cancer in developed regions (76,000
cases or 3.6% of female cancers). In Croatia, cervical
cancer is the 8th most common female cancer, with ap-
proximately 350 new cases and about 100 deaths per year
(33). In 2008, there were 360 cases of cervical cancer (C53)
with the incidence of 15.6 per 100,000 population and
556 precancer cases (carcinoma in situ [CIS]) with the
incidence of 24.2 per 100,000 population (34) (Figure 4).
About 90% of cervical cancer cases are SCC, while
10% are adenocarcinoma (5). Both types of cancer are
mainly caused by HPV type 16 (62% and 50%, respecti-
vely), but adenocarcinoma is significantly more associat-
ed with HPV types 18 (32%) and 45 (12%) (Table 1)
which are phylogenetically closer to each other than to
HPV 16. In a Croatian study on HPV prevalence in
cervical cancer, HPV 16 and HPV 18 were identified in
52% and 28% of SCCs, while in adenocarcinomas there
were found in 27% and 68% cases, respectively (35). The
lower prevalence found in the Croatian study may be
attributed to the lower sensitivity of the genotyping met-
hods used.
Other HR-HPV related cancers
In addition to cervical cancer, HPV infection is as-
sociated with the cancer of the vulva and vagina in wo-
men, cancer of the penis in men, and anal cancer and
oropharyngeal cancer in both sexes (Table 1).
Worldwide, about 30,000 cases of vulvar cancer were
identified in 2008 (36). In Croatia, in the same year, 61
cases were identified with the incidence of 2.7 per 100,000
population (34). Most of these vulvar cancers were SCCs
and HPV positive in 40% cases, mostly for HPV 16
(32%) followed by HPV 18 (4%) (37).
Worldwide, there are about 30,000 and 15,000 new
vulva and vagina cancer cases per year, respectively (36).
In Croatia, in 2008, 61 and 16 cases of vulvar and vaginal
cancer occurred, with the incidence rate of 2.7 and 0.7
per 100,000 population, respectively (34) (Figure 4). Most
of these cancers are SCC affecting older women. The
HPV contribution in vulvar cancer is 40%, mostly HPV
16 (32%) and then HPV 18 (4%) (37). In vaginal cancer
the HPV contribution is higher being 70%, mostly HPV
16 (54%) followed by HPV 18 (8%) (37).
The penile cancer affect about 26,300 men aged over
50 years (36). Similarly to the vulvar cancer, the HPV
contribution is 45%, mostly attributed to the two most
common HR-HPV types, HPV 16 (60) and 18 (13%) but
also to the two most common LR-HPV types, 6 and 11
(together 8%) (38). In Croatia, in 2008, 28 cases of penile
cancer occurred (incidence of 1.3 per 100,000 popu-
lation) (34) (Figure 4).
About 30,400 cases of anal cancer occur annually
worldwide (36). There are slightly more cases in women
(15,900) than men (14,500). In Croatia, in 2008, 19 cases
of anal cancer occurred, 10 and 9 cases in women and
men, respectively, with the incidence of 0.4 per 100,000
population in both sexes (34). The risk of anal carcinoma
is increased among men having sex with men (MSM)
and in immunosuppressed population including those
with the HIV and organ graft recipients (39). Similarly
as the cervix, the anus has a transformation zone that is
highly susceptible to HPV infection. Thus, 97% of anal
cancer cases are HPV positive, mostly with HPV 16 (75%)
followed by HPV 18 (3%) (40).
Globally, about 61,500 oropharyngeal cancers that
occurred in 2008 were associated to HPV infection, in-
cluding lingual cancer (C01), tonsil cancer (C09) and
180 Period biol, Vol 114, No 2, 2012.
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Figure 4. Human papillomavirus (HPV) associated cancers among
men and women in Croatia in the year 2008 (34); *oropharyngeal
cancers represents a sum of C01 (basic linguae), C09 (tonsilla) and
C10 (oropharynx) cancers.
oropharyngeal cancer (C10) (36) (Table 1). They are
much more common in men (48,900 cases) than women
(12,600 cases). In Croatia, in 2008, there were 147 oro-
pharyngeal cancers, 127 in men and 20 in women, with
the incidence of 1.3, 2.1 and 0.6 per 100,000 population,
respectively (34) (Figure 4). HPV-positive oropharyn-
geal tumors are associated with oral sex, age under 60
years, infrequent p53 gene mutation and a more favor-
able clinical outcome, while other HPV-negative cancers
are associated with smoking, excessive alcohol use, age
above 60 years, frequent p53 gene mutation and poor
prognosis (41). HPV contributes to 47% oropharyngeal
carcinomas and 11% of oral cavity (C01 and C09) carci-
nomas, of which 64% and 42% cases in women and men,
respectively (42). HPV16 was the most commonly found
in oropharyngeal carcinomas (90%) and oral carcinomas
(96%) (42).
LR-HPV RELATED DISEASES
Genital warts are highly infectious, with an estimated
transmission rate of >60% and the average incubation
period of 2-8 months. If left untreated, genital warts may
show minimal change, grow larger and more numerous,
or regress spontaneously. Genital warts are largely attri-
butable to LR-HPV types 6 (89%) and 11 (11%) (43).
They are very common in young people (up to 25 years),
spontaneous remissions occur frequently (up to 40%)
(44). However, the psychological burden of the patient as
well as the cost of treatment are very high as incidence
rate is estimated to be 1-2 per 1000 person annually (36).
Laryngeal papillomatosis (also known as recurrent
respiratory papillomatosis) is a rare medical condition
affecting 1.1 per 100,000 children (45). Laryngeal pa-
pillomatosis is caused by HPV types 6 and 11, in which
benign tumors form on the larynx or other areas of the
respiratory tract. Since the disease is most commonly
found in children, the infection may be acquired by
vaginal childbirth from HPV infected mother. Without
treatment, it is potentially fatal as uncontrolled growths
obstruct the airway. These tumors can reoccur frequently,
may require repetitive surgery, and may cause problem
with breathing (46).
PREVENTIVE STRATEGIES
As mentioned before, there are three levels of public
health strategies to prevent cervical cancer: 1) education,
2) prophylactic cervical cancer vaccination, and 3) screen-
ing for early detection of the disease. The knowledge
about the cause of cervical cancer and the way how to
prevent this cancer has been quite recently so, even though
we have advanced HPV-related technologies (HPV test-
ing and HPV vaccination), the delivery and acceptance
of these tools are quite difficult in some countries.
Education of young people about sexually transmitted
diseases, which is poor in Croatia, could largely help pre-
venting HPV infection on the individual basis. Although
some HPV subtypes cause genital warts, most infections
with HPV cause no symptoms; therefore preventive
measures should be conducted in any case. Consistent
use of condoms among partners may reduce but not
eliminate the risk of male-to-female genital HPV trans-
mission since HPV can be present in skin throughout the
anogenital area as well as in genital secretions (47). There
is also evidence that male circumcision reduces the risk
of acquisition of HPV infection among men, which in
turn lowers the risk of subsequent transmission and in-
fection of their partners (48).
Prophylactic HPV vaccination
Prophylactic HPV vaccines were primarily designed
and produced to prevent infection with the most com-
mon cancer causing HPV types, HPV 16 and 18, which
cause about 70% of cervical cancer cases. Nowadays, two
vaccines against HPV 16 and 18 are commercially avail-
able (49) One vaccine is also designed to protect against
HPV 6 and 11 which together cause 90% of genital warts.
Since March 2008, both vaccines have been approved for
use in many countries.
Both vaccines are safe, generally well tolerated and
very immunogenic (100%) against vaccine-included HPV
types. Vaccine efficacy in HPV-negative women in pre-
venting persistent infection with vaccine-included HPV
types and related diseases is very high (>90%) for both
vaccines (50, 51). The primary expectation of vaccine
efficacy was a reduction in precursor lesions by approxi-
mately 50% and in cervical cancer by approximately
70%. This expectation was achieved; in addition, both
vaccines procure cross-protection against non-vaccine-
-HR-HPV types (HPV 31, 33, 45, 52 and 58) and asso-
ciated cervical disease. In HPV-negative women, cross-
-protection by the quadrivalent vaccine was most notable
against HPV 31 (50). In case of bivalent vaccine, the best
individual cross-protection was observed against HPV
31, HPV 33 and HPV 45 (51). Both HPV 31 and HPV 45
are very prevalent in cervical cancer, following HPV
types 16 and 18 in SCC or HPV 18 and 16 in adenocarci-
noma and adenosquamous carcinoma (5). This is parti-
cularly important for protection against adenocarcinoma
and adenosquamous carcinoma which are more difficult
to identify by cervical screening. Together, HPV types 16,
18, 31 and 45 cause 81% of cervical cancer cases (5),
which indicates that cross-protection against those non-
-vaccine-HR-HPV types increases vaccine efficacy. A li-
mitation to HPV vaccination on an individual or popu-
lation basis is its currently very high price (Table 2).
Prevention of other cancers and HPV-related
diseases in men and women
Pap test can also detect precancerous lesion of the
vulva (VIN, vulvar intraepithelial neoplasia) and the
vagina (VaIN, vaginal intraepithelial neoplasia). Prevent-
ing VIN and VaIN by HPV vaccination is far more
efficacious (Table 2). However, as vulvar and vaginal
cancer generally occur in older women, who usually do
not benefit from HPV vaccination, regular gynecological
examination should be performed even after the age of
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60 years when cervical screening is no longer recom-
mended for those women.
For oropharyngeal cancers, primary prevention by
prophylactic HPV vaccination seems to be very promis-
ing. Besides HPV vaccination, especially against HPV
16, there is no secondary prevention by screening of early
stages of the disease as there are no precancerous lesions
that can be easily identified to be prognostic. However,
prognosis of a treated patient can be determined by either
HPV DNA assay, E6/E7 expression assay or p16INK4A
immunostaining (a surrogate marker for HPV infection)
of archival formalin fixed paraffin embedded specimens.
Different treatment options for HPV-positive head and
neck SCC are under consideration as HPV-positive head
and neck SCC usually have better prognosis
Cervical screening
Cervical cancer has a long pre-clinical phase with
precursor lesions that can be identified by cervical cyto-
logy and easily treated using simple outpatient proce-
dures if they are detected at an early stage (Figure 1).
Incidence and mortality rates for cervical cancer in deve-
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TABLE 2
Essential facts about prophylactic cervical cancer vaccines.
Commercially
available vaccines
The quadrivalent vaccine (Gardasil®, Merck & Co., Inc., Whitehouse Station, NJ USA) and the bivalent
vaccine (Cervarix®, GlaxoSmithKline Biologicals, Rixensart, Belgium) have been available since 2006 and
2007, respectively.
Nature of the vaccines Prophylactic vaccines are made by recombinant technology and self-assembled major HPV capsid protein
L1 into VLPs that exhibit morphological and antigenic properties identical to native virions; VLPs do not
contain viral genetic material or live biological product, and are therefore not infectious.
Targeted HPV types The bivalent vaccine is composed of HPV 16 and 18 VLPs with AS04 adjuvant containing aluminum
hydroxide and 3-deacylated monophosphoryl lipid, while the quadrivalent vaccine is composed of HPV 6,
11, 16 and 18 VLPs with aluminum hydroxyphosphate sulphate adjuvant.
Safety Both vaccines are safe, without major adverse effects and generally well tolerated.
Immunogenicity Both vaccines show high immunogenicity (100%) against vaccine-related HPV types.
Higher antibody response against HPV 16 and 18 has been observed for the bivalent vaccine with AS04
adjuvant compared with the same antigens with only aluminum hydroxide adjuvant.
Efficiency HPV vaccines are most efficient if administered to preadolescent or adolescent and young women before
sexual debut.
Boys may be vaccinated as well.
Efficacy High efficacy (>90%) of both vaccines in preventing high-grade cervical disease (CIN2+ and AIS) caused
by HPV 16 and 18 among women who were naive to these HPV types before vaccination, and received all
three doses.
High efficacy in preventing vulvar (VIN) and vaginal (VaIN) intraepithelial lesions caused by
vaccine-related HPV types was observed with the quadrivalent vaccine (not assessed for the bivalent
vaccine) in women who were naive to these HPV types before vaccination, and received all three doses.
Time of protection Both vaccines provide high efficacy for several years after the first dose.
Protection against
non-vaccine HR-HPV
types
Vaccination with the bivalent vaccine has resulted in high seropositivity for non-vaccine types, HPV 31
(>70%) and 45 (>98%) types (phylogenetically close to HPV 16 and 18, respectively).
Both vaccines show some group cross-protection against non-vaccine-HR-HPV types (HPV 31, 33, 45, 52
and 58) and associated cervical disease, as well as individual cross-protection against persistent infection
with the non-vaccine HPV types and related CIN2+.
Protection against
LR-HPV types
Vaccination with the quadrivalent vaccine shows high efficacy in preventing vaccine HPV types 6 and 11
and associated disease.
Therapeutic effect Neither vaccine has shown a therapeutic effect against disease due to HPV types with which subjects were
infected at baseline.
Delivery National immunization HPV vaccination programmes have been introduced faster than any other new
vaccine in the past in more developed countries but not in less developed countries. School-based programmes
seems to be most efficient in coverage.
Limitation High price of the vaccine, complex three dose vaccination schedule, and in some countries low compliance
because of the insufficient advocacy campaigns before delivery.
Vaccinated women have to be regularly screened because HPV vaccines will reduce, but not eliminate, the
risk of cervical cancer.
HPV, human papillomavirus; HR, high-risk; LR, low-risk; VLP, virus-like particles; CIN, cervical intraepithelial neoplasia; AIS, adenocarcinoma in
situ; VIN, vulvar intraepithelial neoplasia; VaIN, vaginal intraepithelial neoplasia.
loped countries have decreased dramatically in the past
25 years largely due to cervical cancer screening using Pap
tests which allows for detection and subsequently treat-
ment of precancerous lesions. Indeed, organized screen-
ing programmes have been proven to reduce cervical
cancer mortality by more than 80%, notably when the
compliance of the target population is high, which is the
case in British Columbia (Canada) and Nordic countries
(Finland, Denmark, Iceland, Norway and Sweden) (52).
Although opportunistic screening can also substan-
tially reduce cervical cancer rates, it will never attain the
levels of reductions seen with an organized programme.
In addition, opportunistic screening has been demon-
strated to over-screen the wealthy and well-educated and
under-screen lower socioeconomic groups and minori-
ties, perpetuating health inequalities and wasting scarce
healthcare resources (53). This has been recognized by
many international, European and national institutions,
including: 1) the World Health Organisation’s recom-
mendation from 2006 (54) stating that cervical screening
should only be offered in organized programmes, rather
than opportunistically, 2) the European Code Against
Cancer from 2003 (55) stating that women from 25 to 60
years of age should be screened at 3 to 5 year intervals
within programmes with proper quality control pro-
cedures, and 3) the new European Guidelines for Quality
Control in Cervical Cancer Screening that specifically
state that cervical cancer screening should not be offered
opportunistically (56).
The limitation of cytology-based screening is the need
to perform it regularly in intervals of generally 2-3 years,
thus increasing the overall cost of the programme but
also the low sensitivity of the Pap test. On the other hand,
a negative HPV test virtually excludes any risk of having
significant prevalent cervical disease and provides the
same degree of protection over 5 years that the accepted
standard of a negative Pap smear provides over 2 years
(57). These results indicate that HPV testing could also
provide substantial cost savings for most countries by
reducing the screening frequency with no increase in risk
for the women being screened. Further savings could be
realized because one laboratory technician could process
more samples for HPV testing in a single working shift
compared to the work done by several cytotechnicians
that is required to process the same number of cytology
samples (56). In addition, training technicians to process
HPV tests is far simpler and quicker than training cyto-
logists to screen Pap smears and, with the dichotomous
result produced by HPV testing, quality assurance pro-
cedures are also far simpler.
The use of HPV testing for primary cervical cancer
screening, either alone or in combination with the Pap
test, has been evaluated in large-scale population-based
randomized clinical trials (RCT) in Canada, Finland,
the Netherlands, Italy, Sweden, and the United King-
dom. From the combined findings of all these RCTs,
HPV testing for primary screening consistently showed
to be substantially more sensitive in detecting severe
cervical lesions, but still less specific than cytology (53,
58). The sensitivity of HPV testing was uniformly high at
all ages, whereas the sensitivity of cytology was substan-
tially better in women over the age of 50 than in younger
women, while the specificity of both tests increased with
age. The loss of specificity could be minimized by avoid-
ing HPV screening in young women (age <30 year),
using more specific HPV tests (RNA test for HPV onco-
genes), and by appropriate triage algorithms.
The cytology could be recommended for triage of
HPV-positive women. Other candidate markers for tri-
age of HPV-positive women such as immunostaining of
p16 or p16/Ki67 are being evaluated (59). In addition,
restricted genotyping of HPV types 16, 18 and 45 should
also be considered for triage of HPV-positive women,
especially because cervical cancer cases associated to those
types appear at the average age of 50.0, 48.2 and 46.8
years, respectively, earlier than any other single HPV
infection (55.5 years) (5). The triage of HPV-positive
screened women is justified especially for HPV types 18
and 45 which are mostly associated with adenocarci-
noma that is more difficult to diagnose by cytology than
SCC.
The overall results from the RCTs support the use of
HPV testing as the sole primary screening test in women
older than 30 years, with cytology reserved for women
who test HPV positive. This approach does not cause
substantial increases in diagnostic work-up and over-
treatment and can be safely implemented within orga-
nized and quality-controlled population-based cervical
screening programmes. Thus, the Netherlands is the first
country with an official recommendation to introduce
HPV-based primary screening (60). However, further
research is needed to establish the optimal age to start
screening (30 or 35), the screening interval in HPV-
-negative women (5 or more years) and the optimal
management of HPV-positive women (cytology, HPV
genotyping or other biomarkers that can identify women
at risk for progressive disease) (Figure 1).
As the size of the vaccinated population increases,
HPV vaccination will produce progressive reductions in
the prevalence of HPV infection and, with this, progres-
sive reductions in the prevalence of cytological abnor-
malities (49). The mathematical consequence of this is
that the PPV of cervical cytology will steadily diminish
eventually to the point when virtually all positives are
false positives and the use of cytology will be neither
cost-effective nor ethically justifiable. At this time, it is
inevitable that cytology will have to be applied to those
who are at highest risk, i.e. those who are HPV-positive.
An important issue for the implementation of HPV
testing as primary screening is its cost-effectiveness in
large-scale population-based screening programmes. The
cost analysis of the NTCC trial indicates that if HPV
testing is applied with cytology triage, a single HPV test
may cost 20-30% more than a conventional Pap test and
still result in the same overall cost per CIN 2+ detected
(61). However, if the price of HPV testing decreases in
the future, better estimates can be expected.
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The situation of cervical cancer prevention in Croatia
is hardly well established, in spite of the fact that op-
portunistic screening has been applied for long time. A
matter of concern is the steady state of the mortality rate.
Thus, appropriate cervical cancer prevention programme
including organized screening with HPV testing as pri-
mary screening and cytology triage, and organized HPV
vaccination should be set up without delay in Croatia
(33, 62, 63).
CONCLUSION
The presented data suggest that cervical cancer is the
most important HPV-related disease although other re-
lated cancers and benign proliferation (genital warts and
laryngeal papillomatosis) represent a high public health
burden. Nationwide population-based organized cer-
vical cancer prevention programmes that include both,
primary prevention (HPV vaccination) and secondary
prevention (screening) with preliminary comprehensive
organized education can effectively reduce cervical can-
cer rates. In addition, offering free services within a
programme of cervical cancer prevention (invitation to
HPV vaccination and screening) could be a solution to
the problem of cervical cancer control but also of other
HPV-related cancer and diseases. However, the price of
HPV vaccination is a limiting factor for its implemen-
tation, especially in low-income countries. Therefore,
cervical cancer policies (vaccination and/or screening)
will probably have to be adapted to the specific needs and
the availability of resources of each country. The choice
of a type of the primary screening test (cytology or HPV
testing), the length of screening intervals, and the nature
of the follow-up strategy will largely influence the cost-
-effectiveness of a cervical cancer screening programme.
However, future cervical cancer control primarily has to
rely on cervical screening, and both vaccinated and non-
-vaccinated women have to be regularly screened be-
cause HPV vaccines will reduce, but not eliminate, the
risk of cervical cancer. A more distant goal is the develop-
ment of therapeutic vaccines as adjuvant treatment for
infections or cancers associated with HPV (64).
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